研究者詳細 - 寺井　崇二

論文 - 寺井　崇二

分割表示 1,104 件中 221 - 240 件目／全件表示 >>

Gastric alarmin release: A warning signal in the development of gastric mucosal diseases

Wu, E., Zhu, J., Ma, Z., Tuo, B., Terai, S., Mizuno, K., Li, T., Liu, X.

Frontiers in Immunology 13 2022年

Steroid therapy still plays a crucial role and could serve as a bridge to the next promising treatments in patients with IgG4-related sclerosing cholangitis: Results of a Japanese nationwide study

Kubota, K., Kamisawa, T., Nakazawa, T., Tanaka, A., Naitoh, I., Takikawa, H., Unno, M., Kawa, S., Masamune, A., Nakamura, S., Okazaki, K., Furumatsu, K., Sawai, S., Goto, T., Okumura, T., Suzuki, D., Otsuka, M., Kobori, I., Tamano, M., Koizumi, M., Hiasa, Y., Kawabe, N., Hirooka, Y., Yamamoto, S., Asano, Y., Inui, K., Horiguchi, A., Watanabe, H., Toya, D., Hatayama, K., Ueki, T., Kinoshita, N., Sugimoto, M., Ohira, H., Mukai, T., Tomita, E., Iwata, K., Shimizu, S., Suetsugu, J., Shimizu, M., Tsuji, K., Ishida, R., Ito, M., Furukawa, R., Sakamoto, N., Araki, M., Tanno, S., Sakamoto, Y., Ito, T., Takai, S., Ikeya, S., Yamada, T., Kudara, N., Shimizu, A., Hanada, K., Ichiki, Y., Kitada, H., Hifumi, M., Kimura, H., Kurosaki, M., Izumi, N., Sumi, H., Haruta, Hayashi, K., Harada, R., Inoue, M., Nakamura, S., Ito, T., Tomishima, K., Isayama, H., Oura, K., Masaki, T., Shimokawahara, N., Tanoue, S., Maemura, K., Ido, A., Mizushima, I., Kawano, M., Yoshida, K., Naganuma, M., Murata, M., Nishio, A., Fujita, Y., Teratani, T., Matsubara, S., Tamai, H., Yoshida, Y., Azemoto, R., Kamata, K., Watanabe, T., Kurosu, T., Koizumi, W., Fujita, J., Seki, H., Ueda, Y., Fukumoto, T., Kousaki, T., Uchida, K., Ochiai, T., Kawasaki, T., Tanaka, M., Ishida, E., Notohara, K., Mori, H., Mori, T., Kawabata, H., Miyata, M., Sakagami, J., Itoh, Y., Shiokawa, M., Seno, H., Watanabe, N., Naitoh, I., Kataoka, H., Aoki, T., Fujishiro, M., Niihara, T., Nishimata, H., Mitoro, A., Yoshiji, H., Yoshida, M., Ikeda, M., Tomita, K., Hokari, R., Hayasaka, K., Amano, Y., Shioji, K., Hayashi, K., Terai, S., Nakajima, M., Yamahana, J., Matsumoto, R., Kikuchi, H., Kanamori, A., Kiriyama, S., Iwatsu, S., Kato, Y., Horiguchi, S., Yagi, T., Okada, H., Ohkawa, K., Hirao, M., Hiramatsu, N., Oza, N., Imamura, H., Baba, T., Nakano, S., Shinobi, T., Ryozawa, S., Motoya, M., Nakase, H., Kinoshita, N., Ito, K., Miyake, T., Kohge, N., Tobita, H., Joshita, S., Umemura, T., Kawaguchi, S., Ohno, K., Sonobe, K., Satoh, A., Shimosegawa, T., Miura, F., Yagi, M., Sano, K., Kin, T., Katanuma, A., Koike, K., Miura, S., Kawashima, Y., Kagawa, T., Azuma, S., Watanabe, M., Honjyo, M., Itoi, T., Honda, A., Kobayashi, K., Asano, T., Mizuno, S., Koike, K., Nishino, T., Taniguchi, H., Tajiri, K., Yasuda, I., Tanaka, Y., Oe, S., Harada, M., Kurata, M., Fukasawa, M., Enomoto, N., Kawaji, Y., Kitano, M., Nishise, Y., Hirakawa, H., Ishizawa, T., Ueno, Y., Kaino, M., Fujimoto, Y., Sakaida, I.

Journal of Hepato-Biliary-Pancreatic Sciences 29 ( 8 ) 2022年

Characteristics of colorectal neuroendocrine tumors in patients prospectively enrolled in a Japanese multicenter study: a first report from the C-NET STUDY

Sekiguchi, M., Hotta, K., Takeuchi, Y., Tanaka, S., Yamamoto, H., Shinmura, K., Harada, K., Uraoka, T., Hisabe, T., Sano, Y., Kondo, H., Horimatsu, T., Kikuchi, H., Kawamura, T., Nagata, S., Yamamoto, K., Tajika, M., Tsuji, S., Kusaka, T., Okuyama, Y., Yoshida, N., Moriyama, T., Hasebe, A., So, S., Kobara, H., Kashida, H., Miyanaga, R., Kato, S., Hayashi, Y., Sada, M., Fukuzawa, M., Kato, H., Takayama, T., Konishi, J., Matsushita, H.-O., Narasaka, T., Ohata, K., Togashi, K., Nakamura, H., Moriichi, K., Oda, Y., K, a, N., Kuwai, T., Terai, S., Sanomura, M., Kitamura, S., Miyamoto, H., Kiriyama, S., Mizuno, C., Saito, Y., Sekine, S., Ito, S., Nakahira, H., Oka, S., Hayashi, Y., Yoshimura, K., Ishikawa, H., Matsuda, T.

Journal of Gastroenterology 57 ( 8 ) 2022年

A difficult-to-diagnose case of Borrmann type IV gastric cancer with marked transverse colon stenosis

Natsui, K., Maruyama, M., Terai, S.

JGH Open 6 ( 11 ) 2022年

The Visceral-to-subcutaneous Adipose Tissue Area Ratio Is Associated with Retreatment in Chronic Pancreatitis Patients with Pancreatolithiasis after Extracorporeal Shock Wave Lithotripsy

Yokoyama, K., Takamura, M., Watanabe, J., Nakamura, A., Sato, Y., Sekine, A., Terai, S.

Internal Medicine 61 ( 24 ) 2022年

Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case–control study

Matsumoto, K., Ohfuji, S., Abe, M., Komori, A., Takahashi, A., Fujii, H., Kawata, K., Noritake, H., Tadokoro, T., Honda, A., Asami, M., Namisaki, T., Ueno, M., Sato, K., Kakisaka, K., Arakawa, M., Ito, T., Tanaka, K., Matsui, T., Setsu, T., Takamura, M., Yasuda, S., Katsumi, T., Itakura, J., Sano, T., Tamura, Y., Miura, R., Arizumi, T., Asaoka, Y., Uno, K., Nishitani, A., Ueno, Y., Terai, S., Takikawa, Y., Morimoto, Y., Yoshiji, H., Mochida, S., Ikegami, T., Masaki, T., Kawada, N., Ohira, H., Tanaka, A.

Journal of Gastroenterology 57 ( 1 ) 2022年

Delayed and Synchronous Recurrence of Breast Cancer Metastases in Multiple Organs

Owaki, T., Hashimoto, S., Umezu, H., Terai, S.

Internal Medicine 61 ( 22 ) 2022年

Intrahepatic Bile Duct Foreign Body With Cholangitis After Pylorus-preserving Pancreatoduodenectomy: Is It a Fish Bone?

Natsui, K., Maruyama, M., Terai, S.

Gastroenterology 163 ( 4 ) 2022年

Endoscopic Findings and Treatment of Gastric Neoplasms in Familial Adenomatous Polyposis

Sato, C., Takahashi, K., Sato, H., Naruse, T., Nakajima, N., Takatsuna, M., Mizuno, K.-I., Hashimoto, S., Takeuchi, M., Yokoyama, J., Kobayashi, M., Terai, S.

Journal of Gastric Cancer 22 ( 4 ) 2022年

Case report: New subtype of gastric adenocarcinoma arising from an H. pylori infection-negative stomach: Foveolar epithelium and mucous neck cell-mixed type adenocarcinoma

Liu, X., Wu, X., Zhu, J., Yagi, K., Ajioka, Y., Terai, S., Mizuno, K., Li, H., Tuo, B., Di, L.

Frontiers in Oncology 12 2022年

A rare case of duodenal variceal bleeding due to extrahepatic portal vein obstruction successfully treated with endoscopic injection sclerotherapy

Hori, A., Watanabe, Y., Takahashi, K., Tonouchi, T., Kimura, N., Setsu, T., Ikarashi, S., Kamimura, H., Yokoyama, J., Terai, S.

Clinical Journal of Gastroenterology 15 ( 3 ) 2022年

Benign Duodenal Stenosis Caused by Huge Mesenteric Hematoma Conservatively Improved with Long-term Use of Double Elementary Diet Tube

Setsu, T., Yokoo, T., Sato, T., Kumagai, M., Motegi, S., Kawata, Y., Ogawa, K., Mizuno, K.-I., Terai, S.

Internal Medicine 61 ( 13 ) 2022年

Gravity assistance enables liver stiffness measurements to detect liver fibrosis under congestive circumstances

Suda, T., Sugimoto, A., Kanefuji, T., Abe, A., Yokoo, T., Hoshi, T., Abe, S., Morita, S., Yagi, K., Takahashi, M., Terai, S.

World Journal of Hepatology 14 ( 4 ) 2022年

Combination therapy of Juzentaihoto and mesenchymal stem cells attenuates liver damage and regresses fibrosis in mice. 国際誌

Takahiro Iwasawa, Shunsuke Nojiri, Atsunori Tsuchiya, Suguru Takeuchi, Takayuki Watanabe, Masahiro Ogawa, Satoko Motegi, Takeki Sato, Masaru Kumagai, Taiki Nakaya, Katsuya Ohbuchi, Miwa Nahata, Naoki Fujitsuka, Masaaki Takamura, Shuji Terai

Regenerative therapy 18 231 - 241 2021年12月

記述言語：英語掲載種別：研究論文（学術雑誌）

Background: Liver cirrhosis is an end-stage multiple liver disease. Mesenchymal stem cells (MSCs) are an attractive cell source for reducing liver damage and regressing fibrosis; additional therapies accompanying MSCs can potentially enhance their therapeutic effects. Kampo medicines exhibit anti-inflammatory and anti-oxidative effects. Here, we investigated the therapeutic effect of MSCs combined with the Kampo medicine Juzentaihoto (JTT) as a combination therapy in a carbon tetrachloride (CCl4)-induced cirrhosis mouse model. Methods: C57BL/6 mice were administered JTT (orally) and/or MSCs (one time, intravenously). The levels of liver proteins were measured in the sera. Sirius Red staining and hydroxyproline quantitation of hepatic tissues and immune cells were conducted, and their associated properties were evaluated. Liver metabolomics of liver tissues was performed. Results: JTT monotherapy attenuated liver damage and increased serum albumin level, but it did not effectively induce fibrolysis. JTT rapidly reduced liver damage, in a dose-dependent manner, after a single-dose CCl4 administration. Furthermore, JTT-MSC combination therapy attenuated liver damage, improved liver function, and regressed liver fibrosis. The combination increased the CD4+/CD8+ ratio. JTT had stronger effects on NK and regulatory T cell induction, whereas MSCs more strongly induced anti-inflammatory macrophages. The combination therapy further induced anti-inflammatory macrophages. JTT normalized lipid mediators, and tricarboxylic acid cycle- and urea cycle-related mediators effectively. Conclusions: The addition of JTT enhanced the therapeutic effects of MSCs; this combination could be a potential treatment option for cirrhosis.

DOI： 10.1016/j.reth.2021.07.002

PubMed

researchmap

Nationwide survey for patients with acute-on-chronic liver failure occurring between 2017 and 2019 and diagnosed according to proposed Japanese criteria

Nobuaki Nakayama, Hayato Uemura, Yoshihito Uchida, Yukinori Imai, Tomoaki Tomiya, Shuji Terai, Hitoshi Yoshiji, Takuya Genda, Akio Ido, Kazuaki Inoue, Naoya Kato, Isao Sakaida, Masahito Shimizu, Yasuhiro Takikawa, Masanori Abe, Ryuzo Abe, Kazuaki Chayama, Kiyoshi Hasegawa, Ayano Inui, Mureo Kasahara, Hiromasa Ohira, Atsushi Tanaka, Hajime Takikawa, Satoshi Mochida

Journal of Gastroenterology 56 ( 12 ) 1092 - 1106 2021年12月

【再生医療への期待〜各疾患領域における現況と展望〜】肝臓領域における細胞を用いた再生医療の将来展望

寺井崇二, 渡邊雄介, 土屋淳紀

Pharma Medica 39 ( 12 ) 37 - 40 2021年12月

記述言語：日本語出版者・発行元：(株)メディカルレビュー社

＜文献概要＞本稿では,肝疾患領域の細胞を用いた再生医療の現状について概説する。2000年から基礎研究成果を基盤に,2003年から開始された肝硬変症に対する自己骨髄細胞投与療法,その後,血管内皮細胞投与療法,さらに自己脂肪組織細胞投与療法が実施されてきた。また,英国エジンバラ大学のForbesらは,肝硬変症に対して自己マクロファージ細胞投与療法を実施し,一方でSokalらは,代償性肝硬変症から急激に肝不全状態になるacute on chronic liver failure(ACLF)に対する,肝臓から採取した肝前駆細胞の投与療法を実施している。さらに,自己間葉系幹細胞を用いた治験も実施されてきた。日本では2017年より他家間葉系幹細胞投与療法の肝硬変症に対する治験を進めてきた(PhaseI,II)。また,2019年よりES細胞由来の肝臓様細胞を門脈より投与する先天性の尿素酵素欠損症に対する医師主導治験が進んでいる。本稿では,現在進んでいる細胞を用いた肝臓疾患に対する細胞を用いた再生療法を俯瞰し紹介する(図1)。

researchmap

その他リンク： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J01750&link_issn=&doc_id=20211223100008&doc_link_id=issn%3D0289-5803%26volume%3D39%26issue%3D12%26spage%3D37&url=http%3A%2F%2Fwww.pieronline.jp%2Fopenurl%3Fissn%3D0289-5803%26volume%3D39%26issue%3D12%26spage%3D37&type=PierOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00005_2.gif

アルコール性肝硬変におけるB型肝炎ウイルス感染の発癌と予後に対する関与についての検討

坂牧僚, 小山究太郎, 森田真一, 阿部寛幸, 上村顕也, 高村昌昭, 寺井崇二

アルコールと医学生物学 40 47 - 49 2021年12月

New cine magnetic resonance imaging parameters for the differential diagnosis of chronic intestinal pseudo-obstruction. 国際誌

Hiroki Sato, Hiroyuki Ogihara, Kazuya Takahashi, Yuzo Kawata, Yuichi Kojima, Kentaro Tominaga, Junji Yokoyama, Yoshihiko Hamamoto, Shuji Terai

Scientific reports 11 ( 1 ) 22974 - 22974 2021年11月

記述言語：英語掲載種別：研究論文（学術雑誌）

Chronic intestinal pseudo-obstruction (CIPO) is a severe and refractory intestinal motility disorder whose diagnosis currently relies on subjective imaging assessments. Cine magnetic resonance imaging (MRI) may potentially improve the quantitative analysis of gastrointestinal motility; however, suitable CIPO detection parameters should be determined. Cine MRI was performed in seven patients with CIPO and 11 healthy controls. The logarithm of the Mahalanobis distance (x1) and distance variation per time (x2) were used as the original parameters to determine CIPO diagnostic thresholds. Furthermore, the correlation between cine MRI findings and CIPO severity was investigated. Threshold values of α = 1.10 and β = 0.15 for x1 and x2, respectively, produced a CIPO diagnosis sensitivity of 1.00 (7/7) and specificity of 0.82 (9/11). The resulting error was 0.11 (2/18). The two parameters were correlated (Pearson's correlation coefficient: - 0.52). Any of the intestinal tracts of patients with severe CIPO requiring home parenteral nutrition belonged to the region defined by x1 ≥ 1.10 and x2 ≤ 0.15. Cine MRI is effective for the quantitative evaluation of small intestinal motility and CIPO diagnosis when using the abovementioned parameters and can be useful for treatment decision-making. However, these parameters have a wide distribution in healthy volunteers; this may complicate the detection of other disorders.

DOI： 10.1038/s41598-021-02268-1

PubMed

researchmap

The risk of cirrhosis and its complications based on PNPLA3 rs738409 G allele frequency. 国際誌

Xue Shao, Haruki Uojima, Taeang Arai, Yuji Ogawa, Toru Setsu, Masanori Atsukawa, Yoshihiro Furuichi, Yoshitaka Arase, Kazue Horio, Hisashi Hidaka, Takahide Nakazawa, Makoto Kako, Tatehiro Kagawa, Katsuhiko Iwakiri, Atsushi Nakajima, Shuji Terai, Yasuhito Tanaka, Wasaburo Koizumi

Digestive diseases (Basel, Switzerland) 40 ( 5 ) 625 - 634 2021年11月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Data regarding the influence of patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism for patients with liver cirrhosis (LC) are scarce. OBJECTIVE: This study assesses the role of the PNPLA3 polymorphism for the development of LC and its complications by the findings of genetic examinations. METHODS: Patients with LC caused by virus (n = 157), alcohol (n = 104), nonalcoholic fatty liver disease (NAFLD) (n = 106), or autoimmune disease (n = 33) and without LC (n = 128) were enrolled. LC were composed of the present and absent of complications, such as variceal bleeding, hepatic ascites, and/or hepatic encephalopathy. To assess the role of the PNPLA3 polymorphism, odds ratio (OR) for the rs738409 variant was calculated for the patients between (i) with LC and without LC in the entire cohort, and (ii) the present and absent of complications in the patients with LC. RESULTS: There was a significant difference among the patients without LC and those with alcohol, NAFLD related LC in the frequency of G alleles (p < 0.001, both). According to complications of LC, the OR for NAFLD related cirrhosis significantly increased in the presence of the two mutated alleles (OR = 3.165; p = 0.046) when the wild type was used as the reference. However, there were no significant risks for the complications in the virus and alcohol related cirrhosis unless there was a presence of G alleles. CONCLUSION: The PNPLA3 polymorphism was associated with the risk of NAFLD related LC and its complications.

DOI： 10.1159/000521062

PubMed

researchmap

Esophageal carcinoma in achalasia patients managed with endoscopic submucosal dissection and peroral endoscopic myotomy: Japan Achalasia Multicenter Study. 国際誌

Hiroki Sato, Yohei Nishikawa, Hirofumi Abe, Hironari Shiwaku, Junya Shiota, Chiaki Sato, Hiroyuki Sakae, Masaki Ominami, Yoshitaka Hata, Hisashi Fukuda, Ryo Ogawa, Jun Nakamura, Tetsuya Tatsuta, Yuichiro Ikebuchi, Hiroshi Yokomichi, Shuji Terai, Haruhiro Inoue

Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 34 ( 5 ) 965 - 973 2021年11月

記述言語：英語掲載種別：研究論文（学術雑誌）

OBJECTIVES: Indications for peroral endoscopic myotomy (POEM) and endoscopic submucosal dissection (ESD) in patients with achalasia concomitant with esophageal carcinoma (EC) are unclear. This study aimed to clarify the role of POEM in cases of achalasia concomitant with EC and to elucidate the indications for ESD and efficient surveillance for EC. METHODS: We conducted a multicenter cohort study at 14 hospitals in Japan, including 3707 cases of achalasia-related esophageal motility disorders (EMDs). Factors contributing to EC risk, the characteristics of EC, and clinical outcomes of POEM/ESD were analyzed. RESULTS: In patients undergoing POEM, screening and surveillance endoscopy throughout a 1-year period resulted in diagnosis of 72.1% new EC cases. Of 62 patients with 123 ECs, 40.3% had multiple or metachronous lesions within 37.5 months. EC was predominantly observed in the middle thoracic esophagus (58.5%) and posteriorly (73.2%). POEM had comparable safety and efficacy in cases of concomitant EC even after ESD. Endoscopic en bloc resection was performed in 95.8% and 89.3% of ECs diagnosed before and after POEM, respectively (P = 0.351); however, ESD on the POEM-line was impaired by fibrosis. Multivariate analysis revealed risk factors for EC, including regular alcohol consumption, a history of smoking, advanced age, and extended disease duration. Alcohol intake and smoking had a synergistic effect on EC development. CONCLUSIONS: Screening and surveillance of POEM help in detecting EC. ESD is feasible in achalasia, although on the POEM-line is challenging. Surveillance endoscopy for EC is recommended for cases with specific risks and a history of ECs.

DOI： 10.1111/den.14197

PubMed

researchmap

　前のページ - 次のページ　

<寺井 崇二>

論文 - 寺井 崇二

<寺井　崇二>

論文 - 寺井　崇二